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and by 2020 there will be a 54% rise in the total number of individuals diagnosed with this disease. These 
are alarming figures that have significant repercussions for the quality of life of individuals and their 
families as well as for the financial stress of health care systems globally. Early detection and proactive 
management of diabetes is essential. The Diamond solution provides diabetes self-management by 
enabling patients to send details about their blood sugar readings at specific times to their nominated 
care coordinator to receive recommendations for diet and exercise and insulin titration. 
Objective: The aim of the study was to assess the usability, acceptability, and fidelity of the Diamond 
diabetes monitoring device for patients with gestational diabetes mellitus (GDM). Specifically assessed 
were (1) patient compliance, (2) patient satisfaction, (3) level of glycemic control achieved, and (4) health 
professional satisfaction. 
Methods: Using a design science research perspective, the Diamond diabetes monitoring device solution 
was adapted to the Australian health care environment. Once the solution was deemed fit for purpose by 
the director of the OB/GYN clinical institute and on securing all relevant ethics approvals, a 2-period 2-arm 
nonblinded crossover clinical trial was conducted for 8 weeks total time with crossover at 4 weeks to 
establish proof of concept, usability, and fidelity. The patient perspective was assessed by using 
structured questionnaires at 4 specific stages of the project, while the clinician perspective was captured 
via semistructured interviews and unstructured questionnaires. 
Results: The 10 patients studied reported preferring standard care with the technology solution to 
standard care alone. Further, all clinicians involved concurred that the technology solution greatly 
assisted their ability to provide higher value patient-centered care. They also noted that it was extremely 
helpful for assisting in systematically monitoring glucose levels and any/all changes and trends. 
Conclusions: Based on these initial findings, we offer a holistic pervasive approach to enable the 
achievement of value-based, patient-centered care in chronic disease management. Key lessons include 
the importance when designing such solutions to focus on the two primary user groups (patients and 
clinicians). 
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Abstract
Background: The World Health Organization notes that diabetes, a chronic disease, is a silent epidemic, and by 2020 there
will be a 54% rise in the total number of individuals diagnosed with this disease. These are alarming figures that have significant
repercussions for the quality of life of individuals and their families as well as for the financial stress of health care systems
globally. Early detection and proactive management of diabetes is essential. The Diamond solution provides diabetes
self-management by enabling patients to send details about their blood sugar readings at specific times to their nominated care
coordinator to receive recommendations for diet and exercise and insulin titration.
Objective: The aim of the study was to assess the usability, acceptability, and fidelity of the Diamond diabetes monitoring
device for patients with gestational diabetes mellitus (GDM). Specifically assessed were (1) patient compliance, (2) patient
satisfaction, (3) level of glycemic control achieved, and (4) health professional satisfaction.
Methods: Using a design science research perspective, the Diamond diabetes monitoring device solution was adapted to the
Australian health care environment. Once the solution was deemed fit for purpose by the director of the OB/GYN clinical institute
and on securing all relevant ethics approvals, a 2-period 2-arm nonblinded crossover clinical trial was conducted for 8 weeks
total time with crossover at 4 weeks to establish proof of concept, usability, and fidelity. The patient perspective was assessed
by using structured questionnaires at 4 specific stages of the project, while the clinician perspective was captured via semistructured
interviews and unstructured questionnaires.
Results: The 10 patients studied reported preferring standard care with the technology solution to standard care alone. Further,
all clinicians involved concurred that the technology solution greatly assisted their ability to provide higher value patient-centered
care. They also noted that it was extremely helpful for assisting in systematically monitoring glucose levels and any/all changes
and trends.
Conclusions: Based on these initial findings, we offer a holistic pervasive approach to enable the achievement of value-based,
patient-centered care in chronic disease management. Key lessons include the importance when designing such solutions to focus
on the two primary user groups (patients and clinicians).
(JMIR Diabetes 2019;4(2):e10368)  doi: 10.2196/10368
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Introduction
Diabetes mellitus is one of the leading chronic diseases, and its
prevalence continues to rise exponentially. The number of
diabetes patients worldwide is estimated to rise to 366 million
in 2030 from 171 million in 2000 [1]. Australia is expected to
be a significant contributor to this projected trend. As of June
2016, more than 1.2 million Australians had been diagnosed
with diabetes and were registered with the National Diabetes
Services Scheme [2]. This number represents those diagnosed
with type 1, type 2, and gestational diabetes.
An estimated 280 Australians develop diabetes every day [2,3].
Moreover, for every person diagnosed with diabetes, it is
estimated that there is another who has yet to be diagnosed,
which doubles the number of people with diabetes. If
uncontrolled or poorly managed, diabetes can lead to chronic
vascular and kidney diseases, strokes, heart attacks, eye diseases,
and neuropathy and, for some individuals, amputations of
extremities and limbs [4,5]. Furthermore, diabetes and its
complications incur significant costs for the health system in
Australia, including costs incurred to careers, government, and
the entire health system.
Treatment of women with gestational diabetes mellitus (GDM)
aims to control maternal, and therefore fetal, hyperglycemia
and the associated tendency of fetal hyperinsulinemia, which
is at the root of fetal complications [6]. After many years of
uncertainty as to the value of such treatment in GDM, two key
trials have now shown benefit for both mother and fetus for
antenatal initiation of lifestyle modification and glucose
monitoring coupled with insulin therapy as necessary [7,8].
Antenatal treatment of detected mild GDM was also associated
with improved health status for women during the antenatal
period and at 3 months after birth, with less postnatal depression
[8]. Specifically, there is agreement in the literature that specific
self-management activities including glucose monitoring, dietary
restrictions, and exercise regimes can result in good outcomes
for mothers and babies, suggesting that self-management
behaviors can be critical [7,9]. More recently in Australia, there
has been a lowering of the threshold level for when a pregnant
woman is classified as having GDM, which immediately led to
a significant increase in the number of women diagnosed with
GDM over and above the growing trend that has been occurring.
This change in classification makes it even more pressing to
find a suitable solution.
Early detection and proactive management of diabetes is
essential [10,11]. A critical treatment imperative is to provide
patients with diabetes appropriate monitoring to enable better
assessment and control of blood glucose and prevent further
complications [12]. It is also essential that a cost-effective
solution convenient to patients and clinicians and least disruptive
to the patient lifestyle be adopted [13].
Inet International developed a pervasive technology solution to
facilitate patient empowerment with their care [14-17]. The
solution uses pervasive mobile technology to transfer critical
information between patient and providers, ensuing in superior
monitoring. This solution has proved successful in assisting to
lower hemoglobin A1c (the universally recognized marker for
diabetes) in trials in Canada and the United States [12].
We report on the findings of our clinical study, based on our
holistic pervasive approach, to enable the achievement of
value-based care in chronic disease management that is
patient-centric and focuses on the two primary user groups
(patients and clinicians). Given that health care costs are an
important aspect of all health care agendas today, we frame our
recommendations against a value-based paradigm, as we believe
this a responsible approach to take. Moreover, a key emergent
aspect of the study was the power-knowledge dynamic that
exists between patients and their clinical care team. We expand
on this finding, noting how it might influence adoption and use
of the technology solution. In particular, we note that when
developing technology solutions, it is important to engage both
user groups; without clinician support and engagement, it is
unlikely that patients will be willing to adopt or use a technology
solution.
The aim of this study was to assess the usability, acceptability,
and fidelity of the pervasive technology solution (Diamond, a
diabetes monitoring device) for patients with GDM and thereby
establish proof of concept. Specifically, the study was designed
to assess (1) patient compliance, (2) patient satisfaction, (3)
level of glycemic control achieved, and (4) health professional
satisfaction. From this, we expected it would be possible to
develop a deeper understanding of the benefits, barriers, and
facilitators as well as any possible negative impacts of such
pervasive mobile solutions in supporting and enabling superior
chronic disease management. In addition, the study served to
answer the following research questions:
• How does a mobile solution enable and support the
value-based care paradigm in the context of chronic disease
management?
• What are the benefits and suitability of such a pervasive
technology solution to self-care?
• What are the key barriers and facilitators for the application
of a pervasive technology solution to support GDM patient
care?
• What are the possibilities of applying the tools and
techniques of data science to enable precision health care
delivery and inform public health care initiatives regarding
better chronic disease management practices and protocols?
• Are patients influenced and persuaded by their clinician to
adopt the solution and is this important in choosing the
solution?
Methods
Study Site
The data site chosen to conduct our study, a large tertiary,
not-for-profit health care system, is situated in Melbourne,
Australia. The Australian health care system is essentially a
two-tier complementary system [18]. This means that all citizens
and permanent residents have basic health care provided by a
national government scheme called Medicare and can choose
to take on additional coverage via private health care insurance.
In Australia, the health care system has historically been
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centered on the practitioners and service providers. It is a highly
fragmented system with both state and federal government
jurisdiction. Hence, there exist many types of health care
providers from solo practice to public hospitals (government
hospitals) to various types of private hospitals. The chosen data
site is in the private system; hence, patients receiving treatment
at this hospital must have private insurance. In addition, the
hospitals in this system are tertiary, which means they conduct
leading research to strive to discover better ways to treat medical
issues, and their not-for-profit status means that any surplus is
reinvested into the system.
Diamond Diabetes Monitoring Device
The Diamond solution was developed by the Canadian company
Inet International to provide diabetes self-management and
monitoring to all patients diagnosed with diabetes. Key aspects
of the solution include full compliance with the US Health
Insurance Portability and Accountability Act; it is totally
pervasive in that it works on any mobile platform (Android,
iOS, etc) and it requires co-use or coadoption by the patient and
their clinical care team.
Diabetic patients provided with the Diamond solution are able
to send details about their blood sugar readings at specific times
(ie, before breakfast, 2 hours after breakfast, 2 hours after lunch,
and 2 hours after dinner) to their nominated care coordinator
(typically a diabetic educator or endocrinologist or other doctor).
On receiving this information, the care coordinator will respond
to the patient with recommendations for diet and exercise and
insulin titration. This exchange happens in real time. In addition,
the solution keeps a log of diet and exercise activity and insulin
use and graphs the blood sugar readings over time so that both
patient and care coordinator can observe what is happening at
any time.
Ethics
The Australian research code of ethics classifies any clinical
intervention on pregnant women at the highest risk and, hence,
the ethics process is at a national approval level and very strict.
Ethics approval was received from the Epworth Human
Research Ethics Committee, but the ethics committee limited
the sample to 10 patients given that the clinical study was the
first of its kind to be administered on pregnant women, and thus,
fell into a high-risk category; if a patient dropped out, for
whatever reason, we were able to add another patient.
To tailor the chosen pervasive technology solution, Diamond,
to the specific health care context of the data site as well as
comply with legal and ethical requirements for use of a
technology solution in a study with pregnant women, it was
necessary to make several tweaks to the technology solution so
that it was both compliant and fit for purpose. We complied
with all requirements and secured all necessary ethics
clearances; to do this in a systematic fashion, we employed a
design science research methodology approach (Multimedia
Appendix 1).
Research Design
A 2-period, 2-arm crossover clinical trial strategy [19] with an
8-week duration per patient was adopted with two equal periods
of 4 weeks each (Figure 1). As we wanted to understand the
benefits, if any, of using a technology solution in addition to
standard care protocols, it was necessary to have 2 arms to the
crossover study design so that all patients experienced standard
care and standard care plus technology. One arm was the control
(ie, standard treatment of GDM by the hospital) and the other
arm was the intervention (ie, standard care plus technology). In
compliance with ethics regulations and laws in Australia, no
patient can be denied standard care, so the intervention arm was
designed as standard care plus the technology solution.
Patients were offered the opportunity to participate in the trial
once a diagnosis of GDM had been made based on a glucose
tolerance test administered between 26 and 28 weeks of
pregnancy. Enrollment in the study was done by the
endocrinologist under the supervision of the consultant
obstetricians and was totally optional. At the time of enrollment,
all pertinent information regarding the study was shared with
patients including the crossover strategy employed. Patients
were asked to complete a short questionnaire exploring
demographic details, their familiarity with technology in general,
and their understanding of GDM. Following enrollment in the
study, patients were randomly allocated to either the standard
care or standard care plus technology arm of the study. All
patients were then educated in the technique of blood glucose
monitoring by a diabetic educator as per standard clinical
practice. They were also educated in the use of traditional or
technology-based recording techniques for blood glucose.
On the advice of the obstetrics and gynecology professionals,
the duration was set at 8 weeks. This was deemed suitable as it
was unlikely a baby would be delivered during this time frame
and we would have time for the patient to experience both arms
of the study. Hence, crossover was set at 4 weeks. As noted by
Rigby [19], it is ideal to have a crossover time so that all
participants can experience treatment with and without the
technology and then comment on the differences. It is also
recommended to have participants start with the technology
solution and cross to without and vice versa so that it is possible
to identify any biases more easily with technology use. The
patient perspective was assessed at four specific stages of the
project (Multimedia Appendix 2, part A):
• Structured questionnaire at the start of the project
• Structured questionnaire at the end of using standard care
• Structured questionnaire at the end of using the technology
solution in conjunction with standard care
• Structured questionnaire at the end of the project
We note that to comply with ethics requirements, we did not
interview patients at the completion of the study as it was
considered too much stress and imposition on a new mother.
As there were two key user groups, patients and clinicians, it
was necessary to also understand findings from the clinical
team. The clinical care perspective included a focus on three
key members of the patient care team: obstetrician,
endocrinologist, and diabetes educator. These individuals were
presented unstructured questionnaires to complete at the start
and end of the study and were also invited to an interview where
they were asked unstructured and semistructured questions
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about the study and their opinions on the role and benefit of the technology solution (Multimedia Appendix 2, parts B and C).
Figure 1. Study design. GDM: gestational diabetes mellitus.
Clinicians participated in both arms of the study and were asked
about the crossover aspects during their interview at the end of
the study. It was our desire to have questionnaires for the
clinicians at the point of crossover, but ethics reviewers stated
that this was superfluous and clinicians should not be given
more questionnaires than necessary, so they were removed to
comply with ethics requirements. The objective of the
questionnaire at the start of the study was to assess ease of use
with technology in day-to-day life determined by mobile
solution used and frequency of use. The questionnaire at the
conclusion of the study was designed to ascertain overall
satisfaction with the technology solution and allow for any
recommendations moving forward.
Results
To address the stated aims and answer the research questions,
this study analyzed the data from two key perspectives: patient
and clinician. Subscribing to the directives of Boyazis [20], the
qualitative data were analyzed by examining the occurrence
and frequency of the a priori themes and then any emergent
themes. Qualitative and qualitative data were collected from
the surveys conducted for both patients and clinicians as well
as from performing basic statistical analysis on the numbers of
patients in the study.
From the patient perspective, the key a priori themes included:
(1) health literacy and understanding regarding diabetes
management, (2) general familiarity with and use of mobile
solutions, (3) standard care, (4) technology solution, and (5)
suggestions to enhance the technology solution. Further,
thematic analysis served to uncover other results from the patient
data collected: (1) their supportive care team played a big role
in their being comfortable with the technology solution because
they trusted their doctor and were confident with the doctor’s
decision and (2) they were committed to doing whatever was
best for their unborn baby’s health, so having timely advice
made them feel they were doing the best for their baby.
Overall, a wonderful initiative. This app makes it
easier for patients with GDM as it’s quick to enter
readings, easy to track trends using graph on website
and an effective and efficient way to communicate
with doctors/nutritionists. For busy mums-to-be
especially this is a fantastic tool, easier than
remembering to call with readings each week.
Excellent concept! [Patient 02]
I could do it [record and check blood glucose levels]
any time of day that was suitable and convenient to
me. Knowing that someone was on the other end and
would contact me if there was a concern/further
information required. Info would be in writing. Could
maintain privacy at work, no need to duck out to have
conversations and report BGL [blood glucose level].
Didn’t need pen and paper. [Patient 07]
In addition, all patients preferred to have standard care with the
mobile solution rather than the standard care approach only.
All patients used mobile phones daily and felt very comfortable
entering the required data. They all had a good understanding
of the protocols they should follow for GDM once they were
explained by their health care professional, and they complied
as best as they could. This is not uncommon, given most
mothers-to-be try to do what is in their unborn baby’s best
interests. At the conclusion of the study, many ideas for further
enhancement were provided by the patients, including having
a recommended food diary, assistance on where to get the
needed food, recommendations for alternate exercise, and voice
recognition to avoid data entry. All patients completed the four
questionnaires.
For consistency, the same a priori themes were used to examine
data collected from the clinicians. Overall, all the clinicians
preferred the technology solution over the standard care only
scenario. A total of 60% (6/10) of clinicians were totally happy
using the app, and it was acceptable “as is” for them, while 40%
(4/10) were happy with the solution but thought it could be
further enhanced and was only useful for typical GDM patients.
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They had reservations about using the solution in the case of
complicated GDM patients. We note that, given ethics
clearances obtained, we could not include high-risk patients in
the study, so we cannot show any results for high-risk patients.
Enhancements included keeping track of weight and blood
pressure on an ongoing basis and graphing these together with
the blood glucose levels.
Further, the clinicians concurred that the technology solution
greatly assisted their ability to save time and made the
monitoring of gestational diabetes more efficient and effective
and was extremely helpful to assist in systematically monitoring
glucose levels, changes, and trends any time regularly. This
enabled them to provide better/optimal care for their patients;
as they noted, having the key data at the right time greatly
assisted them in making prudent decisions. They noted that even
1- to 2-point differences in blood glucose in pregnancy can have
a severe impact on the fetus as it develops, given the resulting
relatively much higher concentration of fetal blood glucose. For
a tiny fetus, every extra second of exposure to a higher
concentration of blood glucose can lead to major issues at birth
and even throughout life.
In terms of usability, there were suggestions to change the
format of patient entry so that it was clear when blood levels
were seriously out of range versus slightly out of range. The
only concern from the diabetes educators pertained to
communicating with patients through the app rather than
face-to-face appointments when dealing with a large sample
size and the likely time requirements this would involve. It is
anticipated that with appropriate staffing and workflow
processes in place, this should not be an added burden, and it
will also lend itself to capturing large amounts of data in a
systematic fashion. These data can then be analyzed, so potential
benefits at a more population health–level might ensue, which
in turn might lead to new insights into diabetes management,
treatment, and even prevention.
The clinicians in the study were particularly interested to further
investigate the potential of the data and how data analytics might
be used to identify key trends. They noted that GDM is the least
understood form of diabetes and having cohorts of data on GDM
patients would provide immense value in assisting to better
understand this disease. They believe that the data collected
could be helpful to examine what diets and exercise and when
these occurred was best with GDM management as well as other
factors including ethnicity and age. To get such a rich picture
and understanding would assist them to develop better protocols
for their patients and even contribute to public health protocols.
The clinicians identified as a major barrier hospital regulations
and legal and government aspects.
In obstetrics there is always much focus if things go
wrong—it is not good for the hospital, and the
government and legal issues are complex, and it tends
to get quite emotional too. Thus it tends to be quite
conservative. Without hospital executive support, it
is not possible to move forward with technology
solutions. This is key, especially in our area.
[OBGYN 01]
In addition, emergent themes developed that focused on the
need for coaching and education, need to redesign existing
operations to make the best use of the efficiency and
effectiveness potential the technology solution affords, and
concerns about time commitments required and managing
expectations regarding response rates by a member of the
clinical care team. Finally, clinicians identified that it would be
good to further enhance the solution to provide monitoring and
management postdelivery to ensure that the mother still controls
her blood glucose levels.
Discussion
Principal Findings
On analysis of the collected data, we contend that acceptability,
usability, and fidelity were established as was initial proof of
concept of the solution. Specifically, all patients using the
technology solution with standard care had better management
of blood glucose levels and were able to monitor and manage
their GDM together with their clinician more effectively and
efficiently when compared with standard care only. This was
based on daily readings, examination of medical records and
reports, and patient and clinician feedback. We note that the
sample size was small (and this was due to ethics restrictions
as already mentioned); however, we believe that by running
further confirmatory studies we can develop a larger evidence
base to further demonstrate the benefits of the Diamond solution
for supporting and enabling superior care for patients with
GDM. Moreover, the study establishes the benefits of such
mobile solutions to both patients and their clinical care team to
be used as an adjunct with standard care protocols. Specific
answers to each of the posed research questions are provided
in Multimedia Appendix 3. We note that while the results
obtained may only be pertinent in the context of GDM, the
developed framework can be generalized to other types of
diabetes and even other types of chronic care interventions that
use mobile solutions. We plan to expand on this in our future
work.
Limitations
Like all studies, this study had a few limitations Sample size
was limited due to ethics requirement. This in turn means that
with such a small sample size generalizability is not possible.
However, this directional data gives insights as to what might
be appropriate in other contexts, which our follow-up research
will investigate more fully. In addition, only one hospital site
was used, and thus the patient catchment was limited not just
by sample size but also by hospital location; it would not be
unsurprising if hospitals located in different socioeconomic
areas had different demographics for the patient population. But
as noted earlier the results obtained serve to provide us with
initial insights and directional data for our follow-up research.
Conclusions
We presented data from an exploratory clinical study designed
to establish proof of concept, in an Australian context, of a
specific pervasive mobile solution, the Diamond diabetes
monitoring device. All patients reported preferring standard
care with the technology solution over standard care alone.
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Further, all clinicians reported that the technology solution
greatly assisted their ability to save time and made the
monitoring of GDM more efficient and effective and was
extremely helpful to assist in systematically monitoring glucose
levels, changes, and trends at any time more regularly. Based
on these findings, we contend that a pervasive technology
solution that is consistent with a value-based care paradigm for
chronic disease management is important. Moreover, such a
solution should be patient-centric, focused on the two primary
user groups (patients and clinicians), and be used in conjunction
with standard care protocols. We believe such a solution has
the potential to represent a paradigm shift for diabetes care and
chronic disease management in general. It is likely that the
consequent paradigm shift in the approach to treating chronic
diseases such as diabetes will provide the needed impetus to
address the rising costs and better means to manage the current
state.
In closing, we note that it is essential with all technology
solutions, but most especially those in health care, to examine
potential risks or negative aspects, if any. Based on the study,
no significant risks became apparent, and given the extensive
rigor applied in the ethics process, we believe any potential
risks were identified during this process and addressed.
However, with scale there may be an impact on clinician
workload, and this should be investigated in future studies.
Thus, establishment of usability, acceptability, and fidelity is
clearly a necessary but not sufficient condition for universal
adoption of a technology solution in health care contexts.
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